Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel

Bibliographic Details
Title: Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
Authors: Miquel Bernardo, Marina Díaz Marsá, Ana González-Pinto, Manuel Martín Carrasco, Víctor Pérez Sola, Pilar Alejandra Sáiz, Eduard Vieta, Marta Torrens, Celso Arango, Benedicto Crespo-Facorro
Source: Neurology and Therapy, Vol 14, Iss 1, Pp 85-98 (2025)
Publisher Information: Adis, Springer Healthcare, 2025.
Publication Year: 2025
Collection: LCC:Neurology. Diseases of the nervous system
Subject Terms: First-episode psychosis, Treatment, Antipsychotic, Schizophrenia, Tolerability, Lurasidone, Neurology. Diseases of the nervous system, RC346-429
More Details: Abstract Introduction For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients. Areas Covered This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real-world practice are provided. Expert Opinion In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2193-8253
2193-6536
Relation: https://doaj.org/toc/2193-8253; https://doaj.org/toc/2193-6536
DOI: 10.1007/s40120-024-00700-y
Access URL: https://doaj.org/article/eedc7389eb05447b83fa76e33d769d49
Accession Number: edsdoj.7389eb05447b83fa76e33d769d49
Database: Directory of Open Access Journals
More Details
ISSN:21938253
21936536
DOI:10.1007/s40120-024-00700-y
Published in:Neurology and Therapy
Language:English